Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components (Data Collectors and Integrators), End Users, Application (Sleep and Movement, Neuro, Respiratory and Cardiological Disorders) and Region – Analysis and Forecast, 2019-2025
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Key Questions Answered in the Report:
The Global Digital Biomarkers Market Report by BIS Research projects the market to grow at a significant CAGR of 40.39% during the forecast period from 2019 to 2025. There are multiple factors that drive the market, such as the surge in the demand for mobile health apps and consumer wearable technology specifically for tracking health. For instance, as of 2019, about 35% of the U.S. adult population (18 to 29 years) track their health with the help of mobile apps while 27% of the adults own and use a wearable device for monitoring heart rate, blood pressure, physical activity, or other vitals.
Furthermore, the data generated from wearable devices are increasingly being validated through studies based on clinical trials. For instance, the number of clinical trials conducted using wearable devices was consistent during the period of 2008 to 2018, i.e. 5-12 trials annually. However, the number surged significantly in 2016 and 2017, with 27 and 32 trials (using mobile devices) commencing each year respectively. The primary reason for this rise in such trials in 2016 and 2017 can be attributed to the considerable surge in the sponsorship for these studies.
Expert Quote
“Cardiovascular disease segment is currently the largest therapeutic segment for the global digital biomarkers market and holds a share of 31.75% of the market, followed by neurodegenerative diseases with a share of 20.63%. During the forecast period, pain management, and mood and behavior segments, are expected to witness the highest CAGR of 59.07% and 45.34%, respectively. The growth in the pain management segment is primarily due to increasing development and adoption of AR/VR solutions for the detection and treatment of chronic pain.”
Scope of the Market Intelligence on Global Digital Biomarkers Market
The purpose of this study is to gain a holistic view of the global digital biomarkers market in terms of various influencing factors such as regional adoption trends, technological advancements, and pricing patterns.
The scope of this report constitutes an in-depth study of the global digital biomarkers market, including a thorough analysis of the products in the market as well as their adoption spanning different regions. The market has been chiefly segmented into component, application, end user, and region. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
Market Segmentation
The Global Digital Biomarkers Market can be segmented on the basis of component type, application, end user, and region. As of 2018, biopharma companies held an estimated 57% of the global digital biomarkers market. Numerous collaborations and partnerships were witnessed in 2017 and 2018, aimed at developing digital solutions for the clinical assessment various disorders such as cardiovascular, neurodegenerative, and respiratory. Some of the notable biopharma companies engaging in partnership activities include, Takeda, Biogen, and Sanofi among others. A significant contribution was also witnessed from healthcare providers, who held an estimated 42% of the global digital biomarkers market in 2018.
During the forecast period (2019-2025), the health insurance payers are expected to evolve as the largest end user segmented in the global digital biomarkers market. The growth rate for this segment is expected to be 44.04% during the forecast period. This high growth rate is primarily due to an increasing use of digital biomarkers by payer groups to effectively devise individualized care plans.
In terms of region, Asia-Pacific is the largest market in the digital biomarkers space and is expected to remain same during the forecast period. North America is also contributing to the growth of this space. The elevated level of smartphone and wearable technology in these regions as well as the high incidence of lifestyle-related diseases are pushing consumers in the region to monitor their medical conditions.
However, during the forecast period, Europe is expected to attain the highest CAGR of 41.99%. The growth is primarily due to increasing standardization and collaboration among key stakeholders in the industry.
Key Companies in the Global Digital Biomarkers Market
Some of the major key players in the global digital biomarkers market include ActiGraph, LLC., Akili Interactive Labs, AliveCor, Inc., Fitbit, Inc., HumanAPI, Novartis, Pfizer Inc. F. Hoffmann-La Roche Ltd, Sanofi, Takeda Pharmaceuticals, and Verily Life Science LLC.
Key Questions Answered in the Report:
- What is the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?
- What are the major market drivers and challenges of, and the opportunities in, the global digital biomarkers market?
- What is the market share of the leading segments and sub-segments of the global digital biomarkers market in 2019 and 2025?
- How did the global digital biomarkers market evolve?
- How is each segment of the global digital biomarkers market expected to grow during the forecast period and what is the expected revenue to be generated by each of the segments by the end of 2025?
- What are the consumer preferences in terms of adoption of wearable technology for the assessment of medical conditions?
- What are the key developmental strategies implemented by the key players to stand out in this market?
- What is the preferred business model used for building digital biomarkers?
- Which area of application is expected to be the highest revenue generator in the global digital biomarkers market during the forecast period?
- Which end user segment is expected to be the highest revenue generator in this industry during the forecast period?
- What is the potential of global digital biomarkers market in the emerging countries during the forecast period?
The Global Digital Biomarkers Market Report by BIS Research projects the market to grow at a significant CAGR of 40.39% during the forecast period from 2019 to 2025. There are multiple factors that drive the market, such as the surge in the demand for mobile health apps and consumer wearable technology specifically for tracking health. For instance, as of 2019, about 35% of the U.S. adult population (18 to 29 years) track their health with the help of mobile apps while 27% of the adults own and use a wearable device for monitoring heart rate, blood pressure, physical activity, or other vitals.
Furthermore, the data generated from wearable devices are increasingly being validated through studies based on clinical trials. For instance, the number of clinical trials conducted using wearable devices was consistent during the period of 2008 to 2018, i.e. 5-12 trials annually. However, the number surged significantly in 2016 and 2017, with 27 and 32 trials (using mobile devices) commencing each year respectively. The primary reason for this rise in such trials in 2016 and 2017 can be attributed to the considerable surge in the sponsorship for these studies.
Expert Quote
“Cardiovascular disease segment is currently the largest therapeutic segment for the global digital biomarkers market and holds a share of 31.75% of the market, followed by neurodegenerative diseases with a share of 20.63%. During the forecast period, pain management, and mood and behavior segments, are expected to witness the highest CAGR of 59.07% and 45.34%, respectively. The growth in the pain management segment is primarily due to increasing development and adoption of AR/VR solutions for the detection and treatment of chronic pain.”
Scope of the Market Intelligence on Global Digital Biomarkers Market
The purpose of this study is to gain a holistic view of the global digital biomarkers market in terms of various influencing factors such as regional adoption trends, technological advancements, and pricing patterns.
The scope of this report constitutes an in-depth study of the global digital biomarkers market, including a thorough analysis of the products in the market as well as their adoption spanning different regions. The market has been chiefly segmented into component, application, end user, and region. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
Market Segmentation
The Global Digital Biomarkers Market can be segmented on the basis of component type, application, end user, and region. As of 2018, biopharma companies held an estimated 57% of the global digital biomarkers market. Numerous collaborations and partnerships were witnessed in 2017 and 2018, aimed at developing digital solutions for the clinical assessment various disorders such as cardiovascular, neurodegenerative, and respiratory. Some of the notable biopharma companies engaging in partnership activities include, Takeda, Biogen, and Sanofi among others. A significant contribution was also witnessed from healthcare providers, who held an estimated 42% of the global digital biomarkers market in 2018.
During the forecast period (2019-2025), the health insurance payers are expected to evolve as the largest end user segmented in the global digital biomarkers market. The growth rate for this segment is expected to be 44.04% during the forecast period. This high growth rate is primarily due to an increasing use of digital biomarkers by payer groups to effectively devise individualized care plans.
In terms of region, Asia-Pacific is the largest market in the digital biomarkers space and is expected to remain same during the forecast period. North America is also contributing to the growth of this space. The elevated level of smartphone and wearable technology in these regions as well as the high incidence of lifestyle-related diseases are pushing consumers in the region to monitor their medical conditions.
However, during the forecast period, Europe is expected to attain the highest CAGR of 41.99%. The growth is primarily due to increasing standardization and collaboration among key stakeholders in the industry.
Key Companies in the Global Digital Biomarkers Market
Some of the major key players in the global digital biomarkers market include ActiGraph, LLC., Akili Interactive Labs, AliveCor, Inc., Fitbit, Inc., HumanAPI, Novartis, Pfizer Inc. F. Hoffmann-La Roche Ltd, Sanofi, Takeda Pharmaceuticals, and Verily Life Science LLC.
EXECUTIVE SUMMARY
1 RESEARCH SCOPE AND METHODOLOGY
1.1 Research Scope
1.2 Global Digital Biomarkers Market: Research Methodology
1.2.1 Primary Data Sources
1.2.2 Secondary Data Sources
2 DIGITAL BIOMARKERS: GLOBAL PERSPECTIVE
2.1 Definition
2.2 Current State of Digital Biomarkers
2.3 Digital Biomarkers Ecosystem
2.3.1 Digital Platforms
2.3.1.1 Wearables Devices
2.3.1.2 Implantable Components/Sensors
2.3.1.3 Ingestible Sensors
2.3.1.4 Ocular Devices
2.3.1.5 Accelerometers
2.3.1.6 Smart Home Systems/IOTs
2.3.1.7 AR/VR Platforms
2.3.1.8 Desktop/Web Apps
2.4 Data Measurements
2.4.1 Physiological Parameters
2.4.2 Behavioral Parameters
2.5 Types of Biomarkers
2.5.1 Wellness
2.5.2 Disease
2.5.3 Drugs
2.6 Industry
2.6.1 Pharmaceutical
2.6.2 Biotechnology/Life Sciences
2.6.3 Medical Devices
2.6.4 App Vendors
2.6.5 Clinical Trials (Clinical Research Organizations)
2.6.6 Technology Vendors
2.7 Digital Biomarkers: Technology Landscape
2.7.1 Artificial Intelligence and Machine Learning
2.7.2 Augmented Reality and Virtual Reality
2.7.3 Blockchain
2.7.4 Edge Computing
2.7.5 Cloud Computing
2.8 Successful Case Studies: Key Therapeutic Areas
2.8.1 Cardiovascular Disease
2.8.2 Parkinson’s Disease
2.8.3 Alzheimer’s Disease
2.8.4 Huntington's disease
3 MARKET DYNAMICS
3.1 Growth Promoting Factors
3.1.1 Increasing Cost of Drug Development
3.1.2 Failure for Drugs for Neurodegenerative Disorder
3.1.3 Regulatory Flexibility Toward Digital Health Solutions
3.1.4 Explosion of Wearable Devices and Increasing Smartphone Penetration
3.2 Market Challenges
3.2.1 Test and Validation
3.2.2 Addressing Biases
3.2.3 Validation Testing
3.2.4 Integration
3.2.5 Cost and Usability
3.3 Market Opportunities
3.3.1 Personalized Medicine
3.3.2 Investment in Voice-Based Digital Biomarkers
3.3.3 Investment in Wearable Technology
3.3.3.1 Early Detection of Neurological Disorders
3.3.3.2 For General Health Management
3.3.3.3 Metabolic, Cardiovascular, and Gastrointestinal Health
3.3.3.4 Maternal, Pre- and Neo-Natal Care
3.3.3.5 Pulmonary Health and Environmental Exposures
4 COMPETITIVE LANDSCAPE
4.1 Key Strategies and Developments
4.1.1 Synergistic Interactions
4.1.2 Product Launches and Enhancements
4.1.3 Business Expansion and Funding Activities
4.1.4 Acquisitions, Approvals, and Others
5 DIGITAL BIOMARKER MARKET OPPORTUNITIES AND GROWTH, 2018-2025 ($MILLION)
5.1 Data Collection (Sensors and Tools that Collect Data)
5.1.1 Wearables Devices
5.1.1.1 Market Estimation and Forecast, 2018-2025
5.1.1.2 Opportunity in Digital Biomarker
5.1.1.3 New Developments
5.1.1.4 Competitive Landscape
5.1.2 Implantable Components/Sensors
5.1.2.1 Market Estimation and Forecast, 2018-2025
5.1.2.2 Opportunity in Digital Biomarker
5.1.2.3 New Developments
5.1.2.4 Competitive Landscape
5.1.3 Mobile/Tablet Apps
5.1.3.1 Market Estimation and Forecast, 2018-2025
5.1.3.2 Opportunity in Digital Biomarker
5.1.3.3 New Developments
5.1.3.4 Competitive Landscape
5.1.4 Platforms
5.1.4.1 Market Estimation and Forecast, 2018-2025
5.1.4.2 Opportunity in Digital Biomarker
5.1.4.3 Competitive Landscape
5.1.5 Desktop Based Software
5.1.5.1 Market Estimation and Forecast, 2018-2025
5.1.5.2 New Developments
5.1.5.3 Competitive Landscape
5.2 Data Integration (Systems that Integrate Data)
5.2.1 Market Estimation and Forecast, 2018-2025
5.2.2 Competitive Landscape
6 GLOBAL DIGITAL BIOMARKERS MARKET (BY APPLICATION)
6.1 Sleep and Movement
6.2 Cardiovascular
6.3 Mood and Behavior
6.4 Pain Management
6.5 Neurodegenerative Disorders
6.6 Respiratory Conditions
7 GLOBAL DIGITAL BIOMARKERS MARKET, BY END USERS
7.1 Biopharmaceutical Companies
7.1.1 Role of Biopharma Companies in the Development of Digital Biomarkers
7.1.2 Major Therapeutic Areas for Biomarkers
7.1.2.1 Respiratory Diseases
7.1.2.2 Neurodegenerative Diseases
7.1.2.3 Cardiovascular Diseases
7.1.2.4 Diabetes
7.2 Payers
7.3 Providers
8 GLOBAL DIGITAL BIOMARKERS MARKET (BY REGION)
8.1 North America
8.1.1 U.S
8.1.1.1 Digital Health Scenario
8.1.1.2 Degree of Adoption of Wearables
8.1.1.3 Degree of Adoption of Mobile Health Applications
8.1.1.4 Local Players in the Digital Biomarker Market
8.1.1.5 Regulatory Scenario
8.1.2 Canada
8.1.2.1 Digital Health Scenario
8.1.2.2 Degree of Adoption of Wearables
8.1.2.3 Degree of Adoption of Mobile Health Applications Adoption
8.1.2.4 Local Digital Biomarker Market
8.1.2.5 Regulatory Scenario
8.1.2.6 Future of Digital Health in Canada
8.2 Europe
8.2.1 Netherlands
8.2.1.1 Digital Health Scenario
8.2.1.2 Level of Wearables Adoption
8.2.1.3 Degree of Adoption of Mobile Health Applications
8.2.1.4 Local Players in the Digital Biomarker Market
8.2.2 Germany
8.2.2.1 Digital Health Scenario
8.2.2.2 Degree of Adoption of Wearables
8.2.2.3 Reluctance to Fitness Trackers
8.2.2.4 Future of Digital Health in Germany
8.2.3 U.K.
8.2.3.1 Digital Health Scenario
8.2.3.2 Degree of Adoption of Wearables
8.2.3.3 Increasing Sales of Smart Watches
8.2.3.4 Abandonment of Wearables
8.2.3.5 Local Players in Wearables
8.2.4 France
8.2.4.1 Digital Health Scenario
8.2.4.2 Degree of Wearables Adoption
8.2.4.3 Local Players in Digital Biomarkers Market
8.2.5 Spain
8.2.5.1 Digital Health Scenario
8.2.5.2 Degree of Adoption of Wearables
8.2.6 Italy
8.2.6.1 Digital Health Scenario
8.2.6.2 Degree of Adoption of Wearables
8.2.6.2.1 Degree of Adoption of Mobile Health Applications
8.2.7 Russia
8.2.7.1 Digital Health Scenario
8.2.7.2 Degree of Adoption of Wearables
8.2.7.3 Degree of Adoption of Mobile Health Applications
8.2.8 Rest-of-Europe
8.2.8.1 Digital Health Scenario
8.2.8.2 Degree of Adoption of Wearables
8.2.8.3 Degree of Adoption of Mobile Health Applications
8.2.8.4 Local Player in Digital Biomarker Market
8.3 Asia-Pacific
8.3.1 China
8.3.1.1 Digital Health Scenario
8.3.1.2 Degree of Adoption of Wearables
8.3.1.3 Degree of Adoption of Mobile Health Applications
8.3.1.4 Local Players in Digital Biomarker Market
8.3.2 Japan
8.3.2.1 Digital Health Scenario
8.3.2.2 Degree of Wearables Adoption
8.3.2.3 Degree of Mobile Health Applications Adoption
8.3.2.4 Local Players in Digital Biomarker Market
8.3.3 South Korea
8.3.3.1 Digital Health Scenario
8.3.3.2 Degree of Adoption of Wearables
8.3.3.3 Degree of Adoption of Mobile Health Applications
8.3.4 India
8.3.4.1 Digital Health Scenario
8.3.4.2 Degree of Adoption of Wearables
8.3.4.3 Degree of adoption of Mobile Health Applications
8.3.4.4 Local Players in Digital Biomarker Market
8.3.5 Australia
8.3.5.1 Digital Health Scenario
8.3.5.2 Level of Wearables Adoption
8.3.5.3 Level of Mobile Health Applications Adoption
8.3.6 Singapore
8.3.6.1 Digital Health Scenario
8.3.6.2 Degree of Adoption of Wearables
8.3.6.3 Degree of Adoption of Mobile Health Applications
8.3.7 Rest-of-Asia-Pacific
8.3.7.1 Digital Health Scenario
8.3.7.2 Degree of adoption of Wearables and Mobile Health Application
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Digital Health Scenario
8.4.1.2 Degree of Adoption of Wearables
8.4.1.3 Degree of Adoption of Mobile Health Applications
8.4.2 Mexico
8.4.2.1 Digital Health Scenario
8.4.2.2 Degree of Adoption of Wearables
8.4.2.3 Degree of Adoption of Mobile Health Applications
8.5 Rest-of-the-World
8.5.1 Saudi Arabia
8.5.1.1 Digital Health Scenario
8.5.1.2 Degree of Adoption of Wearables
8.5.1.3 Degree of Adoption of Mobile Health Applications
8.5.2 UAE
8.5.2.1 Digital Health Scenario
8.5.2.2 Degree of Adoption of Wearables and Mobile Health Applications
8.5.3 Israel
8.5.3.1 Digital Health Scenario
8.5.3.2 Degree of Adoption of Wearables
8.5.4 South Africa
8.5.4.1 Digital Health Scenario
8.5.4.2 Degree of Adoption of Wearables
8.5.4.3 Degree of Adoption of Mobile Health Applications
9 COMPANY PROFILES
9.1 Overview
9.2 ActiGraph, LLC.
9.2.1 Company Overview
9.2.2 Role of ActiGraph, LLC. in Global Digital Biomarkers Market
9.2.3 Product Offerings
9.2.4 Recent Developments
9.2.5 SWOT Analysis: ActiGraph, LLC.
9.3 Akili Interactive Labs
9.3.1 Company Overview
9.3.2 Role of Akili Interactive Labs in the Global Digital Biomarkers Market
9.3.3 Product Portfolio
9.3.4 Recent Developments
9.3.5 SWOT Analysis
9.4 AliveCor Inc.
9.4.1 Company Overview
9.4.2 Role of AliveCor, Inc. in the Global Digital Biomarkers Market
9.4.3 Product Description
9.4.4 Recent Development
9.4.5 SWOT Analysis
9.5 Altoida Inc.
9.5.1 Company Overview
9.5.2 Role of Altoida Inc. in Global Digital Biomarkers Market
9.5.3 Product Profiling
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.6 Amgen Inc
9.6.1 Company Overview
9.6.2 Amgen’s Role in Global Digital Biomarkers Market.
9.6.3 Financials
9.6.4 Key Insights about Financial Health of the Company
9.6.5 SWOT Analysis
9.7 Bayer AG
9.7.1 Company Overview
9.7.2 Role of Bayer Inc. in the Global Digital Biomarkers Market
9.7.3 Financials
9.7.4 Key Insights about Financial Health of the Company
9.7.5 SWOT Analysis
9.8 Biogen Inc
9.8.1 Company Overview
9.8.2 Role of Biogen Inc in Global Digital Biomarkers Market
9.8.3 Financials
9.8.4 Key Insights about Financial Health of the Company
9.8.5 SWOT Analysis
9.9 Eli Lilly and Company
9.9.1 Company Overview
9.9.2 Role of Eli Lilly in Global Digital Biomarkers Market
9.9.3 Financials
9.9.4 Key Insights about Financial Health of the Company
9.9.5 SWOT Analysis
9.10 Evidation Health, Inc
9.10.1 Company Overview
9.10.2 Role of Evidation Health in Global Digital Biomarker Market
9.10.3 Product Offerings
9.10.4 Recent Developments
9.10.5 SWOT Analysis
9.11 Fitbit, Inc.
9.11.1 Company Overview
9.11.2 Role of Fitbit Inc. in Global Digital Biomarker Market.
9.11.3 Recent Developments
9.11.4 Product Offerings
9.11.5 Financials
9.11.6 Key Insights about Financial Health of the Company
9.11.7 SWOT Analysis
9.12 GlaxoSmithKline Plc
9.12.1 Company Overview
9.12.2 Role of GlaxoSmithKline in Global Digital Biomarkers Market
9.12.3 Financials
9.12.4 SWOT Analysis
9.13 Human API
9.13.1 Company Overview
9.13.2 Role of Human API in Global Digital Biomarkers market.
9.13.3 Human API: Product Offering
9.13.4 Key Developments
9.13.5 SWOT Analysis
9.14 Happify Health
9.14.1 Company Overview
9.14.2 Role of Happify Health in Global Digital Biomarker Market
9.14.3 Happify: Product Offerings
9.14.4 Happify: Recent Developments
9.14.5 SWOT Analysis
9.15 IXICO Plc
9.15.1 Company Overview
9.15.2 Role of IXICO plc in the Global Digital Biomarkers Market
9.15.3 Product Offerings
9.15.4 Financials
9.15.5 Key Insights about Financial Health of the Company
9.15.6 SWOT Analysis
9.16 Neurotrack Technology, Inc
9.16.1 Company Overview
9.16.2 Role of Neurotrack Technology, Inc in Global Digital Biomarker Market
9.16.3 Neurotrack Technology: Product Offering
9.16.4 Neurotrack Technology: Recent Developments
9.16.5 SWOT Analysis
9.17 Novartis
9.17.1 Company Overview
9.17.2 Role of Novartis AG in the Global Digital Biomarkers Market
9.17.3 Financials
9.17.4 Key Insights about Financial Health of the Company
9.17.5 SWOT Analysis
9.18 Pfizer Inc.
9.18.1 Company Overview
9.18.2 Role of Pfizer Inc in the Global Digital Biomarkers Market
9.18.3 Product Offerings
9.18.4 Recent Developments of Pfizer Inc in Global Digital Biomarkers Market
9.18.5 Financials
9.18.6 Key Insights about Financial Health of the Company
9.18.7 SWOT Analysis
9.19 F. Hoffmann-La Roche Ltd
9.19.1 Company Overview
9.19.2 Role of F. Hoffmann-La Roche Ltd in the Global Digital Biomarkers Market
9.19.3 Financials
9.19.4 Key Insights about Financial Health of the Company
9.19.5 SWOT Analysis
9.20 Sanofi
9.20.1 Company Overview
9.20.2 Role of Sanofi in Global Digital Biomarker Market
9.20.3 Financials
9.20.4 SWOT Analysis
9.21 Takeda Pharmaceuticals
9.21.1 Company Profile
9.21.2 Role of Takeda Pharmaceuticals in the Global Digital Biomarkers Market
9.21.3 Financials
9.21.4 Key Insights about Financial Health of the Company
9.21.5 SWOT Analysis
9.22 Verily Life Science LLC
9.22.1 Company Overview
9.22.2 Role of Verily Life Science LLC in Global Digital Biomarkers Market
9.22.3 Product Offerings
9.22.4 Recent Developments
9.22.5 SWOT Analysis: Verily Life Science LLC Life Sciences
1 RESEARCH SCOPE AND METHODOLOGY
1.1 Research Scope
1.2 Global Digital Biomarkers Market: Research Methodology
1.2.1 Primary Data Sources
1.2.2 Secondary Data Sources
2 DIGITAL BIOMARKERS: GLOBAL PERSPECTIVE
2.1 Definition
2.2 Current State of Digital Biomarkers
2.3 Digital Biomarkers Ecosystem
2.3.1 Digital Platforms
2.3.1.1 Wearables Devices
2.3.1.2 Implantable Components/Sensors
2.3.1.3 Ingestible Sensors
2.3.1.4 Ocular Devices
2.3.1.5 Accelerometers
2.3.1.6 Smart Home Systems/IOTs
2.3.1.7 AR/VR Platforms
2.3.1.8 Desktop/Web Apps
2.4 Data Measurements
2.4.1 Physiological Parameters
2.4.2 Behavioral Parameters
2.5 Types of Biomarkers
2.5.1 Wellness
2.5.2 Disease
2.5.3 Drugs
2.6 Industry
2.6.1 Pharmaceutical
2.6.2 Biotechnology/Life Sciences
2.6.3 Medical Devices
2.6.4 App Vendors
2.6.5 Clinical Trials (Clinical Research Organizations)
2.6.6 Technology Vendors
2.7 Digital Biomarkers: Technology Landscape
2.7.1 Artificial Intelligence and Machine Learning
2.7.2 Augmented Reality and Virtual Reality
2.7.3 Blockchain
2.7.4 Edge Computing
2.7.5 Cloud Computing
2.8 Successful Case Studies: Key Therapeutic Areas
2.8.1 Cardiovascular Disease
2.8.2 Parkinson’s Disease
2.8.3 Alzheimer’s Disease
2.8.4 Huntington's disease
3 MARKET DYNAMICS
3.1 Growth Promoting Factors
3.1.1 Increasing Cost of Drug Development
3.1.2 Failure for Drugs for Neurodegenerative Disorder
3.1.3 Regulatory Flexibility Toward Digital Health Solutions
3.1.4 Explosion of Wearable Devices and Increasing Smartphone Penetration
3.2 Market Challenges
3.2.1 Test and Validation
3.2.2 Addressing Biases
3.2.3 Validation Testing
3.2.4 Integration
3.2.5 Cost and Usability
3.3 Market Opportunities
3.3.1 Personalized Medicine
3.3.2 Investment in Voice-Based Digital Biomarkers
3.3.3 Investment in Wearable Technology
3.3.3.1 Early Detection of Neurological Disorders
3.3.3.2 For General Health Management
3.3.3.3 Metabolic, Cardiovascular, and Gastrointestinal Health
3.3.3.4 Maternal, Pre- and Neo-Natal Care
3.3.3.5 Pulmonary Health and Environmental Exposures
4 COMPETITIVE LANDSCAPE
4.1 Key Strategies and Developments
4.1.1 Synergistic Interactions
4.1.2 Product Launches and Enhancements
4.1.3 Business Expansion and Funding Activities
4.1.4 Acquisitions, Approvals, and Others
5 DIGITAL BIOMARKER MARKET OPPORTUNITIES AND GROWTH, 2018-2025 ($MILLION)
5.1 Data Collection (Sensors and Tools that Collect Data)
5.1.1 Wearables Devices
5.1.1.1 Market Estimation and Forecast, 2018-2025
5.1.1.2 Opportunity in Digital Biomarker
5.1.1.3 New Developments
5.1.1.4 Competitive Landscape
5.1.2 Implantable Components/Sensors
5.1.2.1 Market Estimation and Forecast, 2018-2025
5.1.2.2 Opportunity in Digital Biomarker
5.1.2.3 New Developments
5.1.2.4 Competitive Landscape
5.1.3 Mobile/Tablet Apps
5.1.3.1 Market Estimation and Forecast, 2018-2025
5.1.3.2 Opportunity in Digital Biomarker
5.1.3.3 New Developments
5.1.3.4 Competitive Landscape
5.1.4 Platforms
5.1.4.1 Market Estimation and Forecast, 2018-2025
5.1.4.2 Opportunity in Digital Biomarker
5.1.4.3 Competitive Landscape
5.1.5 Desktop Based Software
5.1.5.1 Market Estimation and Forecast, 2018-2025
5.1.5.2 New Developments
5.1.5.3 Competitive Landscape
5.2 Data Integration (Systems that Integrate Data)
5.2.1 Market Estimation and Forecast, 2018-2025
5.2.2 Competitive Landscape
6 GLOBAL DIGITAL BIOMARKERS MARKET (BY APPLICATION)
6.1 Sleep and Movement
6.2 Cardiovascular
6.3 Mood and Behavior
6.4 Pain Management
6.5 Neurodegenerative Disorders
6.6 Respiratory Conditions
7 GLOBAL DIGITAL BIOMARKERS MARKET, BY END USERS
7.1 Biopharmaceutical Companies
7.1.1 Role of Biopharma Companies in the Development of Digital Biomarkers
7.1.2 Major Therapeutic Areas for Biomarkers
7.1.2.1 Respiratory Diseases
7.1.2.2 Neurodegenerative Diseases
7.1.2.3 Cardiovascular Diseases
7.1.2.4 Diabetes
7.2 Payers
7.3 Providers
8 GLOBAL DIGITAL BIOMARKERS MARKET (BY REGION)
8.1 North America
8.1.1 U.S
8.1.1.1 Digital Health Scenario
8.1.1.2 Degree of Adoption of Wearables
8.1.1.3 Degree of Adoption of Mobile Health Applications
8.1.1.4 Local Players in the Digital Biomarker Market
8.1.1.5 Regulatory Scenario
8.1.2 Canada
8.1.2.1 Digital Health Scenario
8.1.2.2 Degree of Adoption of Wearables
8.1.2.3 Degree of Adoption of Mobile Health Applications Adoption
8.1.2.4 Local Digital Biomarker Market
8.1.2.5 Regulatory Scenario
8.1.2.6 Future of Digital Health in Canada
8.2 Europe
8.2.1 Netherlands
8.2.1.1 Digital Health Scenario
8.2.1.2 Level of Wearables Adoption
8.2.1.3 Degree of Adoption of Mobile Health Applications
8.2.1.4 Local Players in the Digital Biomarker Market
8.2.2 Germany
8.2.2.1 Digital Health Scenario
8.2.2.2 Degree of Adoption of Wearables
8.2.2.3 Reluctance to Fitness Trackers
8.2.2.4 Future of Digital Health in Germany
8.2.3 U.K.
8.2.3.1 Digital Health Scenario
8.2.3.2 Degree of Adoption of Wearables
8.2.3.3 Increasing Sales of Smart Watches
8.2.3.4 Abandonment of Wearables
8.2.3.5 Local Players in Wearables
8.2.4 France
8.2.4.1 Digital Health Scenario
8.2.4.2 Degree of Wearables Adoption
8.2.4.3 Local Players in Digital Biomarkers Market
8.2.5 Spain
8.2.5.1 Digital Health Scenario
8.2.5.2 Degree of Adoption of Wearables
8.2.6 Italy
8.2.6.1 Digital Health Scenario
8.2.6.2 Degree of Adoption of Wearables
8.2.6.2.1 Degree of Adoption of Mobile Health Applications
8.2.7 Russia
8.2.7.1 Digital Health Scenario
8.2.7.2 Degree of Adoption of Wearables
8.2.7.3 Degree of Adoption of Mobile Health Applications
8.2.8 Rest-of-Europe
8.2.8.1 Digital Health Scenario
8.2.8.2 Degree of Adoption of Wearables
8.2.8.3 Degree of Adoption of Mobile Health Applications
8.2.8.4 Local Player in Digital Biomarker Market
8.3 Asia-Pacific
8.3.1 China
8.3.1.1 Digital Health Scenario
8.3.1.2 Degree of Adoption of Wearables
8.3.1.3 Degree of Adoption of Mobile Health Applications
8.3.1.4 Local Players in Digital Biomarker Market
8.3.2 Japan
8.3.2.1 Digital Health Scenario
8.3.2.2 Degree of Wearables Adoption
8.3.2.3 Degree of Mobile Health Applications Adoption
8.3.2.4 Local Players in Digital Biomarker Market
8.3.3 South Korea
8.3.3.1 Digital Health Scenario
8.3.3.2 Degree of Adoption of Wearables
8.3.3.3 Degree of Adoption of Mobile Health Applications
8.3.4 India
8.3.4.1 Digital Health Scenario
8.3.4.2 Degree of Adoption of Wearables
8.3.4.3 Degree of adoption of Mobile Health Applications
8.3.4.4 Local Players in Digital Biomarker Market
8.3.5 Australia
8.3.5.1 Digital Health Scenario
8.3.5.2 Level of Wearables Adoption
8.3.5.3 Level of Mobile Health Applications Adoption
8.3.6 Singapore
8.3.6.1 Digital Health Scenario
8.3.6.2 Degree of Adoption of Wearables
8.3.6.3 Degree of Adoption of Mobile Health Applications
8.3.7 Rest-of-Asia-Pacific
8.3.7.1 Digital Health Scenario
8.3.7.2 Degree of adoption of Wearables and Mobile Health Application
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Digital Health Scenario
8.4.1.2 Degree of Adoption of Wearables
8.4.1.3 Degree of Adoption of Mobile Health Applications
8.4.2 Mexico
8.4.2.1 Digital Health Scenario
8.4.2.2 Degree of Adoption of Wearables
8.4.2.3 Degree of Adoption of Mobile Health Applications
8.5 Rest-of-the-World
8.5.1 Saudi Arabia
8.5.1.1 Digital Health Scenario
8.5.1.2 Degree of Adoption of Wearables
8.5.1.3 Degree of Adoption of Mobile Health Applications
8.5.2 UAE
8.5.2.1 Digital Health Scenario
8.5.2.2 Degree of Adoption of Wearables and Mobile Health Applications
8.5.3 Israel
8.5.3.1 Digital Health Scenario
8.5.3.2 Degree of Adoption of Wearables
8.5.4 South Africa
8.5.4.1 Digital Health Scenario
8.5.4.2 Degree of Adoption of Wearables
8.5.4.3 Degree of Adoption of Mobile Health Applications
9 COMPANY PROFILES
9.1 Overview
9.2 ActiGraph, LLC.
9.2.1 Company Overview
9.2.2 Role of ActiGraph, LLC. in Global Digital Biomarkers Market
9.2.3 Product Offerings
9.2.4 Recent Developments
9.2.5 SWOT Analysis: ActiGraph, LLC.
9.3 Akili Interactive Labs
9.3.1 Company Overview
9.3.2 Role of Akili Interactive Labs in the Global Digital Biomarkers Market
9.3.3 Product Portfolio
9.3.4 Recent Developments
9.3.5 SWOT Analysis
9.4 AliveCor Inc.
9.4.1 Company Overview
9.4.2 Role of AliveCor, Inc. in the Global Digital Biomarkers Market
9.4.3 Product Description
9.4.4 Recent Development
9.4.5 SWOT Analysis
9.5 Altoida Inc.
9.5.1 Company Overview
9.5.2 Role of Altoida Inc. in Global Digital Biomarkers Market
9.5.3 Product Profiling
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.6 Amgen Inc
9.6.1 Company Overview
9.6.2 Amgen’s Role in Global Digital Biomarkers Market.
9.6.3 Financials
9.6.4 Key Insights about Financial Health of the Company
9.6.5 SWOT Analysis
9.7 Bayer AG
9.7.1 Company Overview
9.7.2 Role of Bayer Inc. in the Global Digital Biomarkers Market
9.7.3 Financials
9.7.4 Key Insights about Financial Health of the Company
9.7.5 SWOT Analysis
9.8 Biogen Inc
9.8.1 Company Overview
9.8.2 Role of Biogen Inc in Global Digital Biomarkers Market
9.8.3 Financials
9.8.4 Key Insights about Financial Health of the Company
9.8.5 SWOT Analysis
9.9 Eli Lilly and Company
9.9.1 Company Overview
9.9.2 Role of Eli Lilly in Global Digital Biomarkers Market
9.9.3 Financials
9.9.4 Key Insights about Financial Health of the Company
9.9.5 SWOT Analysis
9.10 Evidation Health, Inc
9.10.1 Company Overview
9.10.2 Role of Evidation Health in Global Digital Biomarker Market
9.10.3 Product Offerings
9.10.4 Recent Developments
9.10.5 SWOT Analysis
9.11 Fitbit, Inc.
9.11.1 Company Overview
9.11.2 Role of Fitbit Inc. in Global Digital Biomarker Market.
9.11.3 Recent Developments
9.11.4 Product Offerings
9.11.5 Financials
9.11.6 Key Insights about Financial Health of the Company
9.11.7 SWOT Analysis
9.12 GlaxoSmithKline Plc
9.12.1 Company Overview
9.12.2 Role of GlaxoSmithKline in Global Digital Biomarkers Market
9.12.3 Financials
9.12.4 SWOT Analysis
9.13 Human API
9.13.1 Company Overview
9.13.2 Role of Human API in Global Digital Biomarkers market.
9.13.3 Human API: Product Offering
9.13.4 Key Developments
9.13.5 SWOT Analysis
9.14 Happify Health
9.14.1 Company Overview
9.14.2 Role of Happify Health in Global Digital Biomarker Market
9.14.3 Happify: Product Offerings
9.14.4 Happify: Recent Developments
9.14.5 SWOT Analysis
9.15 IXICO Plc
9.15.1 Company Overview
9.15.2 Role of IXICO plc in the Global Digital Biomarkers Market
9.15.3 Product Offerings
9.15.4 Financials
9.15.5 Key Insights about Financial Health of the Company
9.15.6 SWOT Analysis
9.16 Neurotrack Technology, Inc
9.16.1 Company Overview
9.16.2 Role of Neurotrack Technology, Inc in Global Digital Biomarker Market
9.16.3 Neurotrack Technology: Product Offering
9.16.4 Neurotrack Technology: Recent Developments
9.16.5 SWOT Analysis
9.17 Novartis
9.17.1 Company Overview
9.17.2 Role of Novartis AG in the Global Digital Biomarkers Market
9.17.3 Financials
9.17.4 Key Insights about Financial Health of the Company
9.17.5 SWOT Analysis
9.18 Pfizer Inc.
9.18.1 Company Overview
9.18.2 Role of Pfizer Inc in the Global Digital Biomarkers Market
9.18.3 Product Offerings
9.18.4 Recent Developments of Pfizer Inc in Global Digital Biomarkers Market
9.18.5 Financials
9.18.6 Key Insights about Financial Health of the Company
9.18.7 SWOT Analysis
9.19 F. Hoffmann-La Roche Ltd
9.19.1 Company Overview
9.19.2 Role of F. Hoffmann-La Roche Ltd in the Global Digital Biomarkers Market
9.19.3 Financials
9.19.4 Key Insights about Financial Health of the Company
9.19.5 SWOT Analysis
9.20 Sanofi
9.20.1 Company Overview
9.20.2 Role of Sanofi in Global Digital Biomarker Market
9.20.3 Financials
9.20.4 SWOT Analysis
9.21 Takeda Pharmaceuticals
9.21.1 Company Profile
9.21.2 Role of Takeda Pharmaceuticals in the Global Digital Biomarkers Market
9.21.3 Financials
9.21.4 Key Insights about Financial Health of the Company
9.21.5 SWOT Analysis
9.22 Verily Life Science LLC
9.22.1 Company Overview
9.22.2 Role of Verily Life Science LLC in Global Digital Biomarkers Market
9.22.3 Product Offerings
9.22.4 Recent Developments
9.22.5 SWOT Analysis: Verily Life Science LLC Life Sciences
LIST OF TABLES
Table 1: A Comparison Between Examples of Clinical Biomarkers and Digital Biomarkers
Table 2: Percentage of Different Wearable Technology Brands being Used in Clinical Trials (2018)
Table 2.1: Different Categories of Mobile Health Applications
Table 3.1: Major FDA Clearances in 2019
Table 3.2: Leading Wearable Devices and their Features
Table 4.1: Synergistic Activities Share (by Company), January 2016 – September 2019
Table 4.2: Product Launches and Enhancements Share (by Company), January 2016 – September 2019
Table 4.3: Business Expansion and Funding Activities Share (by Company), January 2016 – September 2019
Table 4.4: Key Acquisitions in the global digital biomarkers Space (2019)
Table 6.1: Leading Respiratory Conditions and Related Deaths
Table 8.1: Different Types of Health Tracking People and Their Characteristics
Table 8.2: Different Wearables and Their Adoption Rates in Australia
Table 8.3: Different Wearables and Their Expected Adoption Rates in Australia
Table 8.4: Different Wearables and Their Adoption Rates in Singapore
Table 8.5: Different Wearables and Their Expected Adoption Rates in Singapore
Table 8.6: Different Wearables and Their Adoption Rates in Mexico
Table 8.7: Different Wearables and Their Expected Adoption Rates in Singapore
Table 1: A Comparison Between Examples of Clinical Biomarkers and Digital Biomarkers
Table 2: Percentage of Different Wearable Technology Brands being Used in Clinical Trials (2018)
Table 2.1: Different Categories of Mobile Health Applications
Table 3.1: Major FDA Clearances in 2019
Table 3.2: Leading Wearable Devices and their Features
Table 4.1: Synergistic Activities Share (by Company), January 2016 – September 2019
Table 4.2: Product Launches and Enhancements Share (by Company), January 2016 – September 2019
Table 4.3: Business Expansion and Funding Activities Share (by Company), January 2016 – September 2019
Table 4.4: Key Acquisitions in the global digital biomarkers Space (2019)
Table 6.1: Leading Respiratory Conditions and Related Deaths
Table 8.1: Different Types of Health Tracking People and Their Characteristics
Table 8.2: Different Wearables and Their Adoption Rates in Australia
Table 8.3: Different Wearables and Their Expected Adoption Rates in Australia
Table 8.4: Different Wearables and Their Adoption Rates in Singapore
Table 8.5: Different Wearables and Their Expected Adoption Rates in Singapore
Table 8.6: Different Wearables and Their Adoption Rates in Mexico
Table 8.7: Different Wearables and Their Expected Adoption Rates in Singapore
LIST OF FIGURES
Figure 1: Global Subscriber Base and Smartphone Penetration
Figure 2: Number of Trials that Commenced Each Year using Wearable Technology
Figure 3: Percentage of Completed and Active Clinical Trials Using Wearables
Figure 4: Global Digital Biomarkers Market, by Type (2018-2025)
Figure 5: Global Digital Biomarkers Market, Provider Type: Data Collection (2018-2025)
Figure 6: Global Digital Biomarkers Market, Data Collection System Type (2018-2025)
Figure 7: Global Digital Biomarkers Market, Data Integration System Providers (2018-2025)
Figure 8: Global Digital Biomarkers Market, by Application/Therapeutic Area (2018-2025)
Figure 9: Share of Leading Therapeutic Areas in the Digital Biomarkers Market
Figure 10: Global Digital Biomarkers Market, by End Users (2018-2025)
Figure 11: Current Penetration of Different End User Groups in the Digital Biomarkers Market (2018)
Figure 12: Global Digital Biomarkers Market, by Region (2018-2025)
Figure 1.1: Global Digital Biomarkers Market Segmentation
Figure 1.2: Global Digital Biomarkers Market Research Methodology
Figure 1.3: Primary Research
Figure 1.4: Secondary Research
Figure 1.5: Data Triangulation
Figure 1.6: Bottom-up Approach (Segment-wise Analysis)
Figure 1.7: Top-down Approach (Segment-wise Analysis)
Figure 1.8: Assumptions and Limitations
Figure 1.9: Considered Factors for Data Prediction and Modeling
Figure 1.10: Scope Definition for the Global Digital Biomarkers Market
Figure 2.1: Major Components of Digital Biomarkers Market
Figure 2.2: A flowchart depicting the conversion of healthcare data to a digital biomarker
Figure 2.3: Different Populations of Data Producers of Digital Biomarkers
Figure 3.1: Failure rate of different phase II drugs
Figure 3.2: Rising Research and Development (R&D) Cost of the FDA Cleared Drugs.
Figure 3.3: Number of Alzheimer's Disease Drug no Longer Under Development
Figure 4.1: Share of Key Developments and Strategies, January 2016 – September 2019
Figure 5.1: Global Digital Biomarker Data Collection Market, 2018-2025
Figure 5.2: Global Wearable Devices Market, 2018-2025
Figure 5.3: Global Implantable Components/Biosensors Market, 2018-2025
Figure 5.4: Global Mobile/Tablet Apps Market, 2018-2025
Figure 5.5: Global Platform Market, 2018-2025
Figure 5.6: Global Desktop Based Software Market, 2018-2025
Figure 5.7: Global Data Integration Systems Market, 2018-2025
Figure 6.1: Global Digital Biomarkers Market, Application Type: Sleep and Movement, 2018-2025
Figure 6.2: Global Digital Biomarkers Market, Application Type: Cardiovascular, 2018-2025
Figure 6.3: Global Digital Biomarkers Market, Application Type: Mood and Behaviour, 2018-2025
Figure 6.4: Global Digital Biomarkers Market, Application Type: Pain Management, 2018-2025
Figure 6.5: Global Digital Biomarkers Market, Application Type: Neurodegenerative Disorders, 2018-2025
Figure 6.6: Disease burden in the U.S. (by Therapeutic Area)
Figure 6.7: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, 2018-2025
Figure 7.1: Potential Use Cases of Digital Biomarkers (From an End User Perspective)
Figure 7.2: Global Digital Biomarkers Market, End User Type: Biopharma companies, 2018-2025
Figure 7.3: Global Digital Biomarkers Market, End User Type: Health Insurance Payers, 2018-2025
Figure 7.4: Global Digital Biomarkers Market, End User Type: Healthcare Providers, 2018-2025
Figure 8.1: North America Digital Biomarkers Market, 2018-2025
Figure 8.2: Factors Influencing Digital Biomarkers Market in North America
Figure 8.3: U.S. Digital Biomarkers Market, 2018-2025
Figure 8.4: U.S. Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.5: Canada Digital Biomarkers Market, 2018-2025
Figure 8.6: Canada Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.7: Mobile Health Applications: Usage Areas
Figure 8.8: Europe Digital Biomarkers Market, 2018-2025
Figure 8.9: Factors Influencing Digital Biomarkers Market in Europe
Figure 8.10: Netherlands Digital Biomarkers Market, 2018-2025
Figure 8.11: Netherlands Digital Biomarkers Market, By Settings, 2018-2025
Figure 8.12: Germany Digital Biomarkers Market, 2018-2025
Figure 8.13: Germany Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.14: U.K. Digital Biomarkers Market, 2018-2025
Figure 8.15: U.K. Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.16: France Digital Biomarkers Market, 2018-2025
Figure 8.17: France Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.18: Spain Digital Biomarkers Market, 2018-2025
Figure 8.19: Spain Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.20: Italy Digital Biomarkers Market, 2018-2025
Figure 8.21: Italy Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.22: Russia Digital Biomarkers Market, 2018-2025
Figure 8.23: Russia Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.24: Belgium Digital Biomarkers Market, 2018-2025
Figure 8.25: Sweden Digital Biomarkers Market, 2018-2025
Figure 8.26: Denmark Digital Biomarkers Market, 2018-2025
Figure 8.27: Norway Digital Biomarkers Market, 2018-2025
Figure 8.28: Asia-Pacific Digital Biomarkers Market, 2018-2025
Figure 8.29: Factors Influencing Digital Biomarkers Market in Asia-Pacific
Figure 8.30: China Digital Biomarkers Market, 2018-2025
Figure 8.31: China Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.32: Japan Digital Biomarkers Market, 2018-2025
Figure 8.33: Japan Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.34: South Korea Digital Biomarkers Market, 2018-2025
Figure 8.35: South Korea Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.36: India Digital Biomarkers Market, 2018-2025
Figure 8.37: India Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.38: Australia Digital Biomarkers Market, 2018-2025
Figure 8.39: Australia Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.40: Singapore Digital Biomarkers Market, 2018-2025
Figure 8.41: Latin America Digital Biomarkers Market, 2018-2025
Figure 8.42: Factors Influencing Digital Biomarkers Market in Latin America
Figure 8.43: Brazil Digital Biomarkers Market, 2018-2025
Figure 8.44: Brazil Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.45: Mexico Digital Biomarkers Market, 2018-2025
Figure 8.46: Mexico Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.47: Rest-of-the-World Digital Biomarkers Market, 2018-2025
Figure 8.48: Factors Influencing Digital Biomarkers Market in Rest-of-the-World
Figure 8.49: Saudi Arabia Digital Biomarkers Market, 2018-2025
Figure 8.50: Saudi Arabia Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.51: UAE Digital Biomarkers Market, 2018-2025
Figure 8.52: UAE Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.53: Israel Digital Biomarkers Market, 2018-2025
Figure 8.54: Israel Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.55: South Africa Digital Biomarkers Market, 2018-2025
Figure 8.56: South Africa Digital Biomarkers Market (by Setting), 2018-2025
Figure 9.1: Total Number of Companies Profiled
Figure 9.2: ActiGraph, LLC.: SWOT Analysis
Figure 9.3: Akili Interactive Labs: SWOT Analysis.
Figure 9.4: AliveCor Inc.: SWOT Analysis
Figure 9.5: Altoida Inc.: SWOT Analysis
Figure 9.6: Amgen Inc: Overall Financials, 2016-2018
Figure 9.7: Amgen Inc. Revenue (by Region), 2016-2018
Figure 9.8: Amgen Inc R&D Expenditure, 2016-2018
Figure 9.9: Amgen Inc: SWOT Analysis
Figure 9.10: Bayer Inc.: Overall Financials, 2016-2018
Figure 9.11: Bayer Inc: Revenue (by Segment), 2016-2018
Figure 9.12: Bayer Inc: Revenue (by Region), 2016-2018
Figure 9.13: Bayer Inc: R&D Expenditure, 2016-2018
Figure 9.14: Bayer Inc: SWOT Analysis
Figure 9.15: Biogen Inc: Overall Financials, 2016-2018
Figure 9.16: Biogen: Revenue (by Region), 2016-2018
Figure 9.17: Biogen: R&D Expenditure, 2016-2018
Figure 9.18: Biogen Inc: SWOT Analysis
Figure 9.19: Eli Lilly and Company: Overall Financials, 2016-2018
Figure 9.20: Eli Lilly and Company: Revenue (by Segment), 2016-2018
Figure 9.21: Eli Lilly and Company: Revenue (by Region), 2016-2018
Figure 9.22: Eli Lilly and Company: R&D Expenditure, 2016-2018
Figure 9.23: Eli Lilly and Company: SWOT Analysis
Figure 9.24: Evidation Health: SWOT Analysis
Figure 9.25: Fitbit Inc.: Overall Financials, 2016-2018
Figure 9.26: Fitbit Inc.: Revenue (by Region), 2016-2018
Figure 9.27: Fitbit, Inc.: R&D Expenditure, 2016-2018
Figure 9.28: Fitbit Inc.: SWOT Analysis
Figure 9.29: GlaxoSmithKline: Overall Financials, 2016-2018
Figure 9.30: GlaxoSmithKline: Revenue (by Business Segments), 2016-2018
Figure 9.31: GlaxoSmithKline: Revenue (by Region), 2016-2018
Figure 9.32: GlaxoSmithKline: Research and Development Investment, 2016-2018
Figure 9.33: GlaxoSmithKline: SWOT Analysis
Figure 9.34: HumanAPI: SWOT Analysis
Figure 9.35: Happify: SWOT Analysis
Figure 9.36: IXICO plc: Overall Financials, 2016-2018
Figure 9.37: IXICO plc: Revenue (by Region), 2016-2018
Figure 9.38: IXICO plc: R&D Expenditure, 2016-2018
Figure 9.39: IXICO plc: SWOT Analysis
Figure 9.40: Neurotrack Technology: SWOT Analysis
Figure 9.41: Novartis AG: Overall Financials, 2016-2018
Figure 9.42: Novartis AG: Revenue (by Segment), 2016-2018
Figure 9.43: Novartis AG: Revenue (by Region), 2016-2018
Figure 9.44: Novartis AG, 2016-2018
Figure 9.45: Novartis AG: SWOT Analysis
Figure 9.46: Pfizer,Inc: Overall Financials, 2016-2018
Figure 9.47: Pfizer Inc: Revenue (by Segment), 2016-2018
Figure 9.48: Pfizer Inc: Revenue (by Region), 2016-2018
Figure 9.49: Pfizer Inc.: R&D Expenditure, 2016-2018
Figure 9.50: Pfizer Inc.: SWOT Analysis
Figure 9.51: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 9.52: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 9.53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 9.54: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 9.55: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 9.56: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 9.57: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 9.58: Sanofi: Overall Financials, 2016-2018
Figure 9.59: Sanofi: Revenue (by Business Segments), 2016-2018
Figure 9.60: Sanofi: Revenue (by Region), 2016-2018
Figure 9.61: Sanofi: Research and Development (R&D) Investment, 2016-2018
Figure 9.62: Sanofi: SWOT Analysis
Figure 9.63: Takeda Pharmaceuticals: Overall Financials, 2016-2018
Figure 9.64: Takeda Pharmaceuticals: Revenue (by Region), 2016-2018
Figure 9.65: Takeda Pharmaceuticals: R&D Expenditure, 2016-2018
Figure 9.66: Takeda Pharmaceuticals: SWOT Analysis
Figure 9.67: Verily Life Science LLC: SWOT Analysis
Figure 1: Global Subscriber Base and Smartphone Penetration
Figure 2: Number of Trials that Commenced Each Year using Wearable Technology
Figure 3: Percentage of Completed and Active Clinical Trials Using Wearables
Figure 4: Global Digital Biomarkers Market, by Type (2018-2025)
Figure 5: Global Digital Biomarkers Market, Provider Type: Data Collection (2018-2025)
Figure 6: Global Digital Biomarkers Market, Data Collection System Type (2018-2025)
Figure 7: Global Digital Biomarkers Market, Data Integration System Providers (2018-2025)
Figure 8: Global Digital Biomarkers Market, by Application/Therapeutic Area (2018-2025)
Figure 9: Share of Leading Therapeutic Areas in the Digital Biomarkers Market
Figure 10: Global Digital Biomarkers Market, by End Users (2018-2025)
Figure 11: Current Penetration of Different End User Groups in the Digital Biomarkers Market (2018)
Figure 12: Global Digital Biomarkers Market, by Region (2018-2025)
Figure 1.1: Global Digital Biomarkers Market Segmentation
Figure 1.2: Global Digital Biomarkers Market Research Methodology
Figure 1.3: Primary Research
Figure 1.4: Secondary Research
Figure 1.5: Data Triangulation
Figure 1.6: Bottom-up Approach (Segment-wise Analysis)
Figure 1.7: Top-down Approach (Segment-wise Analysis)
Figure 1.8: Assumptions and Limitations
Figure 1.9: Considered Factors for Data Prediction and Modeling
Figure 1.10: Scope Definition for the Global Digital Biomarkers Market
Figure 2.1: Major Components of Digital Biomarkers Market
Figure 2.2: A flowchart depicting the conversion of healthcare data to a digital biomarker
Figure 2.3: Different Populations of Data Producers of Digital Biomarkers
Figure 3.1: Failure rate of different phase II drugs
Figure 3.2: Rising Research and Development (R&D) Cost of the FDA Cleared Drugs.
Figure 3.3: Number of Alzheimer's Disease Drug no Longer Under Development
Figure 4.1: Share of Key Developments and Strategies, January 2016 – September 2019
Figure 5.1: Global Digital Biomarker Data Collection Market, 2018-2025
Figure 5.2: Global Wearable Devices Market, 2018-2025
Figure 5.3: Global Implantable Components/Biosensors Market, 2018-2025
Figure 5.4: Global Mobile/Tablet Apps Market, 2018-2025
Figure 5.5: Global Platform Market, 2018-2025
Figure 5.6: Global Desktop Based Software Market, 2018-2025
Figure 5.7: Global Data Integration Systems Market, 2018-2025
Figure 6.1: Global Digital Biomarkers Market, Application Type: Sleep and Movement, 2018-2025
Figure 6.2: Global Digital Biomarkers Market, Application Type: Cardiovascular, 2018-2025
Figure 6.3: Global Digital Biomarkers Market, Application Type: Mood and Behaviour, 2018-2025
Figure 6.4: Global Digital Biomarkers Market, Application Type: Pain Management, 2018-2025
Figure 6.5: Global Digital Biomarkers Market, Application Type: Neurodegenerative Disorders, 2018-2025
Figure 6.6: Disease burden in the U.S. (by Therapeutic Area)
Figure 6.7: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, 2018-2025
Figure 7.1: Potential Use Cases of Digital Biomarkers (From an End User Perspective)
Figure 7.2: Global Digital Biomarkers Market, End User Type: Biopharma companies, 2018-2025
Figure 7.3: Global Digital Biomarkers Market, End User Type: Health Insurance Payers, 2018-2025
Figure 7.4: Global Digital Biomarkers Market, End User Type: Healthcare Providers, 2018-2025
Figure 8.1: North America Digital Biomarkers Market, 2018-2025
Figure 8.2: Factors Influencing Digital Biomarkers Market in North America
Figure 8.3: U.S. Digital Biomarkers Market, 2018-2025
Figure 8.4: U.S. Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.5: Canada Digital Biomarkers Market, 2018-2025
Figure 8.6: Canada Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.7: Mobile Health Applications: Usage Areas
Figure 8.8: Europe Digital Biomarkers Market, 2018-2025
Figure 8.9: Factors Influencing Digital Biomarkers Market in Europe
Figure 8.10: Netherlands Digital Biomarkers Market, 2018-2025
Figure 8.11: Netherlands Digital Biomarkers Market, By Settings, 2018-2025
Figure 8.12: Germany Digital Biomarkers Market, 2018-2025
Figure 8.13: Germany Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.14: U.K. Digital Biomarkers Market, 2018-2025
Figure 8.15: U.K. Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.16: France Digital Biomarkers Market, 2018-2025
Figure 8.17: France Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.18: Spain Digital Biomarkers Market, 2018-2025
Figure 8.19: Spain Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.20: Italy Digital Biomarkers Market, 2018-2025
Figure 8.21: Italy Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.22: Russia Digital Biomarkers Market, 2018-2025
Figure 8.23: Russia Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.24: Belgium Digital Biomarkers Market, 2018-2025
Figure 8.25: Sweden Digital Biomarkers Market, 2018-2025
Figure 8.26: Denmark Digital Biomarkers Market, 2018-2025
Figure 8.27: Norway Digital Biomarkers Market, 2018-2025
Figure 8.28: Asia-Pacific Digital Biomarkers Market, 2018-2025
Figure 8.29: Factors Influencing Digital Biomarkers Market in Asia-Pacific
Figure 8.30: China Digital Biomarkers Market, 2018-2025
Figure 8.31: China Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.32: Japan Digital Biomarkers Market, 2018-2025
Figure 8.33: Japan Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.34: South Korea Digital Biomarkers Market, 2018-2025
Figure 8.35: South Korea Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.36: India Digital Biomarkers Market, 2018-2025
Figure 8.37: India Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.38: Australia Digital Biomarkers Market, 2018-2025
Figure 8.39: Australia Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.40: Singapore Digital Biomarkers Market, 2018-2025
Figure 8.41: Latin America Digital Biomarkers Market, 2018-2025
Figure 8.42: Factors Influencing Digital Biomarkers Market in Latin America
Figure 8.43: Brazil Digital Biomarkers Market, 2018-2025
Figure 8.44: Brazil Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.45: Mexico Digital Biomarkers Market, 2018-2025
Figure 8.46: Mexico Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.47: Rest-of-the-World Digital Biomarkers Market, 2018-2025
Figure 8.48: Factors Influencing Digital Biomarkers Market in Rest-of-the-World
Figure 8.49: Saudi Arabia Digital Biomarkers Market, 2018-2025
Figure 8.50: Saudi Arabia Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.51: UAE Digital Biomarkers Market, 2018-2025
Figure 8.52: UAE Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.53: Israel Digital Biomarkers Market, 2018-2025
Figure 8.54: Israel Digital Biomarkers Market (by Setting), 2018-2025
Figure 8.55: South Africa Digital Biomarkers Market, 2018-2025
Figure 8.56: South Africa Digital Biomarkers Market (by Setting), 2018-2025
Figure 9.1: Total Number of Companies Profiled
Figure 9.2: ActiGraph, LLC.: SWOT Analysis
Figure 9.3: Akili Interactive Labs: SWOT Analysis.
Figure 9.4: AliveCor Inc.: SWOT Analysis
Figure 9.5: Altoida Inc.: SWOT Analysis
Figure 9.6: Amgen Inc: Overall Financials, 2016-2018
Figure 9.7: Amgen Inc. Revenue (by Region), 2016-2018
Figure 9.8: Amgen Inc R&D Expenditure, 2016-2018
Figure 9.9: Amgen Inc: SWOT Analysis
Figure 9.10: Bayer Inc.: Overall Financials, 2016-2018
Figure 9.11: Bayer Inc: Revenue (by Segment), 2016-2018
Figure 9.12: Bayer Inc: Revenue (by Region), 2016-2018
Figure 9.13: Bayer Inc: R&D Expenditure, 2016-2018
Figure 9.14: Bayer Inc: SWOT Analysis
Figure 9.15: Biogen Inc: Overall Financials, 2016-2018
Figure 9.16: Biogen: Revenue (by Region), 2016-2018
Figure 9.17: Biogen: R&D Expenditure, 2016-2018
Figure 9.18: Biogen Inc: SWOT Analysis
Figure 9.19: Eli Lilly and Company: Overall Financials, 2016-2018
Figure 9.20: Eli Lilly and Company: Revenue (by Segment), 2016-2018
Figure 9.21: Eli Lilly and Company: Revenue (by Region), 2016-2018
Figure 9.22: Eli Lilly and Company: R&D Expenditure, 2016-2018
Figure 9.23: Eli Lilly and Company: SWOT Analysis
Figure 9.24: Evidation Health: SWOT Analysis
Figure 9.25: Fitbit Inc.: Overall Financials, 2016-2018
Figure 9.26: Fitbit Inc.: Revenue (by Region), 2016-2018
Figure 9.27: Fitbit, Inc.: R&D Expenditure, 2016-2018
Figure 9.28: Fitbit Inc.: SWOT Analysis
Figure 9.29: GlaxoSmithKline: Overall Financials, 2016-2018
Figure 9.30: GlaxoSmithKline: Revenue (by Business Segments), 2016-2018
Figure 9.31: GlaxoSmithKline: Revenue (by Region), 2016-2018
Figure 9.32: GlaxoSmithKline: Research and Development Investment, 2016-2018
Figure 9.33: GlaxoSmithKline: SWOT Analysis
Figure 9.34: HumanAPI: SWOT Analysis
Figure 9.35: Happify: SWOT Analysis
Figure 9.36: IXICO plc: Overall Financials, 2016-2018
Figure 9.37: IXICO plc: Revenue (by Region), 2016-2018
Figure 9.38: IXICO plc: R&D Expenditure, 2016-2018
Figure 9.39: IXICO plc: SWOT Analysis
Figure 9.40: Neurotrack Technology: SWOT Analysis
Figure 9.41: Novartis AG: Overall Financials, 2016-2018
Figure 9.42: Novartis AG: Revenue (by Segment), 2016-2018
Figure 9.43: Novartis AG: Revenue (by Region), 2016-2018
Figure 9.44: Novartis AG, 2016-2018
Figure 9.45: Novartis AG: SWOT Analysis
Figure 9.46: Pfizer,Inc: Overall Financials, 2016-2018
Figure 9.47: Pfizer Inc: Revenue (by Segment), 2016-2018
Figure 9.48: Pfizer Inc: Revenue (by Region), 2016-2018
Figure 9.49: Pfizer Inc.: R&D Expenditure, 2016-2018
Figure 9.50: Pfizer Inc.: SWOT Analysis
Figure 9.51: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 9.52: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 9.53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 9.54: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 9.55: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 9.56: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 9.57: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 9.58: Sanofi: Overall Financials, 2016-2018
Figure 9.59: Sanofi: Revenue (by Business Segments), 2016-2018
Figure 9.60: Sanofi: Revenue (by Region), 2016-2018
Figure 9.61: Sanofi: Research and Development (R&D) Investment, 2016-2018
Figure 9.62: Sanofi: SWOT Analysis
Figure 9.63: Takeda Pharmaceuticals: Overall Financials, 2016-2018
Figure 9.64: Takeda Pharmaceuticals: Revenue (by Region), 2016-2018
Figure 9.65: Takeda Pharmaceuticals: R&D Expenditure, 2016-2018
Figure 9.66: Takeda Pharmaceuticals: SWOT Analysis
Figure 9.67: Verily Life Science LLC: SWOT Analysis
